- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1502KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 1045KB)
Apalutamide – November 2021
Apalutamide (mHSPC): Tablet 60 mg; Erlyand®
Last updated
30 May 2025